Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2016 1
2017 1
2021 2
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Döhner H, et al. Among authors: pullarkat va. Blood. 2024 Nov 21;144(21):2211-2222. doi: 10.1182/blood.2024024944. Blood. 2024. PMID: 39133921 Free PMC article.
The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine may be suboptimal. ...
The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive ch …
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Pullarkat VA, et al. Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16. Cancer Discov. 2021. PMID: 33593877 Free PMC article. Clinical Trial.
The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) in pediatric and adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia or lymphoblastic lymphom …
The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase I dose-escalation stu …
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM, Pullarkat VA, Komrokji RS. Zeidan AM, et al. Among authors: pullarkat va. Crit Rev Oncol Hematol. 2017 Sep;117:57-66. doi: 10.1016/j.critrevonc.2017.07.002. Epub 2017 Jul 12. Crit Rev Oncol Hematol. 2017. PMID: 28807236 Review.
Development of IO and tissue iron deposition can increase the risk of cardiac, hepatic, and endocrine toxicities, infection, and progression to acute myeloid leukemia. Iron chelation therapy (ICT) is an option for lower-risk MDS patients to reduce their degree of IO and po …
Development of IO and tissue iron deposition can increase the risk of cardiac, hepatic, and endocrine toxicities, infection, and progression …
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
Pullarkat VA, Levis M, McCloskey J, Mannis GN, Strickland SA, Fathi AT, Lin TL, Bhatt VR, Vanniyasingam T, Chakravarthy D, Lutska Y, Faderl S, Cheung RS, Erba HP. Pullarkat VA, et al. Blood Neoplasia. 2025 Jun 3;2(4):100123. doi: 10.1016/j.bneo.2025.100123. eCollection 2025 Nov. Blood Neoplasia. 2025. PMID: 40932876 Free PMC article.
Preclinical data suggest CPX-351, approved for patients with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, may exhibit synergy with targeted agents, suggesting a rationale for combining targeted agents with CPX-351 …
Preclinical data suggest CPX-351, approved for patients with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with …
Trial of Enasidenib Maintenance Post-Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2-Mutated Acute Myeloid Leukemia.
Salhotra A, Bejanyan N, Yang D, Mokhtari S, Knobler D, Park G, Malki MMA, Sandhu KS, Faramand R, Aldoss I, Artz AS, Aribi A, Elmariah H, Sahebi F, Mansour J, Ball BJ, Agrawal V, Li L, Pullarkat VA, Forman SJ, Marcucci G, Stein AS, Nakamura R. Salhotra A, et al. Among authors: pullarkat va. Transplant Cell Ther. 2026 Jan;32(1):76.e1-76.e12. doi: 10.1016/j.jtct.2025.09.013. Epub 2025 Sep 19. Transplant Cell Ther. 2026. PMID: 40976487 Clinical Trial.
The relapse rate at 1 year is approximately 30% in acute myeloid leukemia (AML) patients with an IDH2 mutation who undergo allogeneic hematopoietic cell transplantation (alloHCT). ...Grade 3 adverse effects were mainly hematologic and gastrointestinal toxicities. The 2-ye …
The relapse rate at 1 year is approximately 30% in acute myeloid leukemia (AML) patients with an IDH2 mutation who undergo allogeneic …
Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
Jeyakumar N, Aldoss I, Yang D, Mokhtari S, Gendzekhadze K, Khaled S, O'Donnell M, Palmer J, Song JY, Marcucci G, Stein AS, Forman SJ, Pullarkat VA, Chen W, Wu X, Nakamura R. Jeyakumar N, et al. Among authors: pullarkat va. Eur J Haematol. 2021 Jun;106(6):851-858. doi: 10.1111/ejh.13622. Epub 2021 Mar 24. Eur J Haematol. 2021. PMID: 33721333 Clinical Trial.
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, Bu X, Thein M, Lee M, Brynes RK. Pullarkat VA, et al. Am J Hematol. 2003 May;73(1):12-7. doi: 10.1002/ajh.10322. Am J Hematol. 2003. PMID: 12701114 Free article.
The majority of patients with systemic mastocytosis with associated clonal, hematological non-mast cell lineage disease (SM-AHNMD) have a myeloid stem cell malignancy including myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative disorders, acute myeloid leukemi …
The majority of patients with systemic mastocytosis with associated clonal, hematological non-mast cell lineage disease (SM-AHNMD) have a my …
BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA, Newman EM. Pullarkat VA, et al. Cancer Discov. 2016 Oct;6(10):1082-1083. doi: 10.1158/2159-8290.CD-16-0921. Cancer Discov. 2016. PMID: 27698099
Venetoclax is an oral drug with an excellent side-effect profile that has the potential to revolutionize acute myeloid leukemia (AML) therapy in two areas. Venetoclax-based combination therapies could be a bridge to hematopoietic cell transplant with curative intent for pa …
Venetoclax is an oral drug with an excellent side-effect profile that has the potential to revolutionize acute myeloid leukemia (AML) …